Boston Scientific touts positive data from next-gen SCS

Boston Scientific (NYSE:BSX) said yesterday that data from its Precision Spectra spinal cord stimulator study showed 1.5 times better pain relief and 2 times better lower back pain relief than its previous generation SCS.

The analysis examined 213 patients treated with the new Precision Spectra and 130 patients treated with the previous generation Precision Plus, as well as 25 patients treated with the Spectra and a different set of leads, the Marlborough, Mass.-based company said.

“The results are exciting because we looked at consecutive patients – some with only low back pain – in a real-world setting. This is strong clinical evidence of the effectiveness of the Precision Spectra system in treating the types of challenging chronic pain patients that physicians see every day,” lead investigator Dr. Julie Pilitsis of Albany Medical College said in a press release.

Results from the Spectra-treated patients showed a reduction in pain from a baseline, 1-10 scale pain rating average of 7.17 to an average 2.98 after 24 months with the implant, the company said.

“We designed the Precision Spectra SCS system to achieve even better outcomes when treating low back pain. These real-world clinical data demonstrate that the Precision Spectra system with our proprietary neural targeting software is a significant scientific advancement in pain management,” neuromodulation president Maulik Nanavaty said in a prepared statement.

Boston Scientific won FDA approval for the device in April, 2013 and won CE Mark approval in the European Union in late 2012.

The post Boston Scientific touts positive data from next-gen SCS appeared first on MassDevice.

from MassDevice http://ift.tt/1KZC05T